Posted by Michael Wonder on 21 Sep 2023
Biocon Biologics receives European Commission approval for Yesafili, biosimilar aflibercept
20 September 2023 - Biocon Biologics, a subsidiary of Biocon, has announced that the European Commission granted marketing authorisation in the European Union for Yesafili, a biosimilar of Aflibercept.
The European Commission decision follows the EMA’s CHMP positive opinion recommending approval of Yesafili in July.
